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BRIEF COMMUNICATION
The disruption of atherosclerotic plaques and the
formation of thrombi are major causes of mor-
bidity and mortality in cardiovascular diseases.1
Atherosclerotic stenosis is an important cause of
ischemic stroke in Western populations,2 and its
prevalence is also increasing in Chinese.3 The
detection of vulnerable plaques is important for
risk stratification and proper treatment.
Inflammation plays a significant role in athero-
sclerosis and contributes to subsequent plaque
rupture.4 Macrophages and vascular smooth
muscle cells, as important components of vul-
nerable plaques, are the sources of matrix 
metalloproteinase (MMP) production.4,5 Immu-
nochemical findings have shown increased ex-
pression of MMPs in carotid plaques, especially
MMP-1.6–8 However, the clinical significance of
circulating MMP-1 in carotid stenosis remains
unclear. We hypothesized that higher serum levels
of MMP-1 is associated with significant carotid
atherosclerosis, and should increase after plaque
manipulation.
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High tissue matrix metalloproteinase (MMP) activity has been reported to be associated with atheroscle-
rosis and plaque rupture. The aim of this study was to elucidate the diagnostic value of serum MMP-1 in
carotid stenosis and its dynamic change after stenting. We measured high-sensitivity C-reactive protein
(hs-CRP) and MMP-1 in 37 patients with carotid stenosis (≥ 50%) and 84 controls. In 30 patients who un-
derwent stenting, MMP-1 and hs-CRP were assessed immediately after stenting. We found that patients
with carotid stenosis exhibited significantly higher MMP-1 compared with controls, but there was no dif-
ference in hs-CRP. Moreover, MMP-1 was elevated immediately after stenting. In multivariate analyses,
MMP-1 was negatively correlated with statin and angiotensin converting enzyme inhibitor/angiotensin-II
receptor blocker use in controls. In conclusion, higher levels and rapid surge after stenting in patients with
carotid stenosis indicate that MMP-1 is an important composition of plaques, and suggest its potential
role in the assessment of plaque burden and stability of carotid stenosis. [J Formos Med Assoc 2008;
107(1):93–98]
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Methods
We studied 37 patients who were scheduled for
elective angiography with ≥ 50% cervical carotid
stenosis by ultrasound between January 2004 and
July 2005. Patients with cerebral infarction within
1 month, cerebral hemorrhage within 6 months,
bedridden status or diagnosis of dementia, and
major operation or bleeding within 6 months were
excluded. At the time of enrolment, all patients
received aspirin and clopidogrel, and medications
were kept stable for at least 1 month. During the
same period, 84 apparently healthy subjects re-
ferred from the Health Management Center of
National Taiwan University Hospital were recruited
as controls. None had any history or clinical evi-
dence of cardiovascular disease, and all had nor-
mal neck ultrasound examinations. The study
was approved by the institutional review board
and written informed consent was obtained.
In patients with significant carotid stenosis,
selective digital subtraction angiography was per-
formed, and the indication for stenting was steno-
sis diameter ≥ 50% in symptomatic and ≥ 70% in
asymptomatic lesions.9,10 Any event occurring dur-
ing admission was recorded as peri-procedural.
New neurologic deficits or death occurring during
follow-up were documented. Neck ultrasound
was performed at 1 week, 1, 3 and 6 months, and
then annually after the procedure.10
Blood samples were taken after an overnight
fast. Peripheral venous blood was collected before
angiography and immediately after stent deploy-
ment (≤ 30 minutes). In controls, blood samples
were taken on the day of neck ultrasound. Serum
high sensitivity C-reactive protein (hs-CRP) was
measured by a chemiluminescent enzyme-labeled
immunometric assay (Immulite C-Reactive Pro-
tein; Diagnostic Products Co., Los Angeles, USA).
MMP-1 was determined with a commercially
available enzyme-linked immunosorbent assay
(Amersham, UK).
Statistical analysis
Data are shown as mean ± standard deviation.
Comparisons between groups were made using
Student’s t test and χ2 test or Mann-Whitney 
U test for continuous and categorical variables,
respectively. The strength of associations was es-
timated by Pearson’s correlation coefficient (r).
MMP-1 levels before and after interventions were
compared using the paired t test. General linear
model was used to analyze the contribution to
MMP-1 levels. Logistic regression models were
used to estimate the effects of variables in pre-
dicting clinical events by entering variables that
had p < 0.10 in univariate analysis, and odds ratio
(OR) and 95% confidence intervals (CI) were
determined. A p value less than 0.05 indicated
statistical significance. Data analyses were per-
formed with Stata version 8 (Stata, TX, USA).
Results
Study population
The clinical presentations of carotid stenosis 
patients included transient ischemic attack or
cerebrovascular accident in 25 (69%), amaurosis
fugax in four (11%), recent onset of neurologic
symptoms (< 6 weeks) in 18 (49%), and angi-
ographically documented coronary artery disease
in 21 (57%). The primary lesions were located in
the internal carotid artery in 34 patients (92%)
and the common carotid artery in the other three
(8%). Eleven patients (30%) had bilateral carotid
lesions, and 18 (49%) had concomitant arterial
stenosis (≥ 70%) involving basilar, intracranial,
cervical vertebral or subclavian arteries.
Patients with carotid stenosis were signifi-
cantly older, male, hypertensive and with a his-
tory of smoking. Carotid stenosis patients were
more likely to be on statin and angiotensin con-
verting enzyme inhibitor (ACEI)/angiotensin-II
receptor blocker (ARB) therapy, but the inci-
dence of hyperlipidemia and diabetes were not
significantly different between the two groups
(Table 1).
MMP-1 levels were significantly higher in 
patients with carotid stenosis, but not hs-CRP
levels (Figure A). By multivariable logistic regres-
sion, the independent predictors for significant
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carotid stenosis were age, male gender, hyperten-
sion, current smoker and MMP-l (Table 2).
Clinical outcomes in patients with 
significant carotid stenosis
Thirty patients underwent successful stenting.
The only peri-procedural event was acute throm-
boembolism involving the left middle cerebral 
artery in a patient with left internal carotid steno-
sis. Small acute infarct was noted on computed
tomography (CT) and the patient was discharged
with mild dysarthria and aphasia.
Patients were followed for 21 ± 9 months
(range, 6–35 months) after the index procedure.
No recurrent symptom or restenosis occurred
within 6 months. Five subjects had new ischemic
Table 1. Characteristics of patients with/without significant carotid stenosis*
Carotid stenosis (n = 37) Controls (n = 84) p
Age (yr) 69.2 ± 9.7 57.7 ± 11.0 < 0.0001
Male gender 35 (95) 45 (54) < 0.0001
BMI (kg/m2) 24.9 ± 3.2 24.7 ± 3.5 NS
Abdominal girth (cm) 85.2 ± 7.4 85.9 ± 9.2 NS
Glucose (mg/dL) 120.1 ± 40.7 113.7 ± 37.2 NS
TC (mg/dL) 197.1 ± 41.3 204.5 ± 31.7 NS
Triglycerides (mg/dL) 158.4 ± 79.3 153.2 ± 104.2 NS
hs-CRP (mg/L) 2.29 ± 3.20 1.92 ± 2.87 NS
MMP-1 (ng/mL) 7.53 ± 7.52 1.92 ± 1.37 < 0.0001
Hypertension 31 (84) 27 (32) < 0.0001
Diabetes mellitus 19 (51) 37 (44) NS
Hyperlipidemia 13 (35) 39 (46) NS
Smoker < 0.0001
Current 11 (30) 3 (4)
Former 14 (38) 6 (7)
Statin therapy 14 (38) 12 (14) 0.003
PPAR-γ agonist 2 (5) 7 (8) NS
ACEI/ARB 21 (57) 27 (32) 0.005
*Data are presented as mean ± standard deviation or n (%). BMI = body mass index; TC = total cholesterol; hs-CRP = high-sensitivity
C-reactive protein; MMP-1 = matrix metalloproteinase-1; PPAR = peroxisome-proliferator-activated receptor; ACEI = angiotensin 
converting enzyme inhibitor; ARB = angiotensin-II receptor blocker; NS = not significant.
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Figure. (A) Comparisons of matrix metalloproteinase-1 (MMP-1) and high-sensitivity C-reactive protein (hs-CRP) serum
levels between patients with carotid stenosis (n = 37) and controls (n = 84). Significantly higher levels of MMP-1 in 
patients with carotid stenosis were noted, but not hs-CRP. (B) Serial changes in MMP-1 levels in carotid stenosis patients
with stenting (n = 30). A rapid surge in MMP-1 after stenting was found.
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cerebral stroke or transient ischemic attack 24 ±
8 months later (range, 11–30 months)—four re-
lated to intracranial stenosis but with no signifi-
cant restenosis and one who developed significant
intrastent restenosis as well as multiple intracra-
nial arterial stenoses on CT angiography. Overall,
three subjects developed late-onset significant
restenosis, proved by angiography, after a follow-
up of 24 ± 5 months (range, 21–30 months).
Only one diabetic patient died due to plantar
ulcer and septic shock 2 years after index inter-
vention. There were no significant predictors of
late-onset restenosis. The only independent risk
factor of late-onset cerebral ischemic events was
current smoker (OR, 3.04; 95% CI, 0.61–5.48;
p = 0.014).
MMP-1 levels: relation to cardiovascular 
risk factors and prognosis
In the overall cohort, the correlation between
MMP-1 and hs-CRP was rather insignificant (r =
0.2, p = NS). In contrast, MMP-1 levels were mod-
erately associated with age (r = 0.24, p = 0.008)
and male gender (r = 0.25, p = 0.005).
In the control group, MMP-1 was negatively
correlated with statin (r = –0.35; p = 0.001), 
peroxisome-proliferator-activated receptor (PPAR)-
γ agonist (r = –0.25; p = 0.02) and ACEI/ARB (r =
–0.33; p=0.002). After multivariate adjustment for
medication, MMP-1 levels were still indepen-
dently associated with the use of statin and ACEI/
ARB (Table 3). In addition, diabetic controls (n =
28) had significantly higher body mass index
(26.1 ± 3.3 kg/m2 vs. 24.0 ± 3.4 kg/m2; p = 0.009),
fasting glucose (138.5 ± 45.0 mg/dL vs. 101.3 ±
25.1 mg/dL; p < 0.0001), HbA1c (7.58 ± 1.63 mg/
dL vs. 5.94 ± 1.00 mg/dL; p < 0.0001), triglycerides
(200.8 ± 148.4 mg/dL vs. 130.3 ± 64.2 mg/dL; p =
0.003), and hs-CRP (2.84 ± 4.1 mg/L vs. 1.45 ±
1.87 mg/L; p = 0.036) as compared with non-
diabetic controls. No statistical difference in
MMP-1 levels could be found between diabetic
and non-diabetic controls, partly due to common
use of statin (r = 0.58), PPAR-γ agonist (r = 0.43)
and ACEI/ARB (r = 0.54) therapy (all p < 0.0001).
In 30 patients who underwent intervention,
MMP-1 increased immediately after stenting
(7.70 ± 7.99 ng/mL to 11.50 ± 7.43 ng/mL; p =
0.006; Figure B), but hs-CRP did not (1.76 ±
1.44 mg/L to 1.76 ± 1.48 mg/L; p = NS). However,
there were no significant differences in baseline
and post-stenting surge of MMP-1 levels between
patients with and without late events.
Discussion
In the current study, we demonstrated higher se-
rum level of MMP-1 in patients with significant
Table 2. Association of risk factors in significant carotid stenosis as determined by multiple logistic regression
(stepwise method, adjusted R2 = 0.57, p < 0.0001)
β coefficient Standard error (β) p
Age (yr) 0.088 0.035 0.012
Male gender 1.903 0.865 0.028
Hypertension 2.971 0.894 0.001
Current smoker 2.929 0.960 0.002
MMP-1 (ng/mL) 0.379 0.155 0.015
MMP-1 = matrix metalloproteinase-1.
Table 3. Correlation of matrix metalloproteinase-1
levels and medication in the control group
as determined by linear regression analysis
(adjusted R2 = 0.16, p = 0.0001)
β coefficient
Standard 
p
error (β)
Statin −1.070 0.411 0.011
ACEI/ARB −0.722 0.308 0.021
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin-
II receptor blocker.
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carotid stenosis and its rapid elevation after stent-
ing. These findings suggest that MMP-1 is an im-
portant component of advanced carotid plaques.
It has been reported that ruptured plaques
contain numerous macrophages, which produce
MMPs that are capable of degrading extracellular
matrix, which may contribute to thinning of 
fibrous cap and embolic events.5–8,11 Of various
MMPs, MMP-1 mainly degrades type 1 collagen,
which is the most abundant extracellular matrix
protein. In the present study, we documented a
strong correlation between circulating MMP-1
and advanced carotid disease. Rapid increase in
MMP-1 after plaque manipulation but not hs-CRP
suggests that the surge was caused by plaque 
disruption, not systemic inflammation.
Although several epidemiologic studies have
demonstrated a consistent relationship between
higher CRP levels and increased risk of cardio-
vascular events, this association is not independ-
ent of traditional cardiovascular risk factors.12
This may indicate that MMP-1, in contrast to hs-
CRP, is a more specific marker for carotid steno-
sis. Unexpectedly, our study showed that serum
MMP-1 level was not elevated in diabetic sub-
jects, and wide use of statins13 and ACEI/ARB14
could partly explain this phenomenon, suggest-
ing that plaque stabilization could be possible
by using such drugs with anti-inflammatory and
anti-mitogenic effects.
Some limitations of this study were that age
and gender were not well matched between cases
and controls, and the sample size was relatively
small and less homogeneous. A majority of the
studied subjects were on aggressive medical con-
trol, which might have attenuated the differences
in serum biomarkers between patients with carotid
stenosis and controls. However, we still confirmed
the strong association between circulating MMP-1
and significant carotid atherosclerosis by multi-
ple regression analyses. The present study failed
to show a significant correlation between MMP-1
and clinical outcome. In addition, a high preva-
lence of concurrent atherosclerosis is noted in
patients with carotid stenosis;15 the higher MMP-1
levels might reflect the extensive atherosclerosis,
not only carotid disease. The clinical impact of
MMP-1 in detection of plaque instability, disease
progression, and prediction of peri-procedural
complications or late events need to be established
with a larger study population and outcome-
based studies.
Our findings indicate that MMP-1 has a role
in the pathophysiology of atherosclerosis, and it
might be used as an adjunctive biomarker to 
detect advanced carotid plaque burden. Further-
more, as it is released into the circulation imme-
diately after plaque manipulation, it may also be
used to monitor spontaneous plaque disruption
and predict clinical events.
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